

Agneta Nordberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1122772/agneta-nordberg-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

365
papers

26,307
citations

79
h-index

152
g-index

383
ext. papers

29,793
ext. citations

5.8
avg, IF

6.9
L-index

#	Paper	IF	Citations
365	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
364	Lack of fibrillar amyloid plaques but hypometabolism and astrogliosis in autosomal dominant variant AB Parc Alzheimer's disease.. <i>Molecular Psychiatry</i> , 2021 , 26, 5471	15.1	
363	Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer's disease.. <i>Journal of Neurochemistry</i> , 2021 ,	6	2
362	Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer's disease cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1093-1102	8.8	7
361	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021 , 298, 517-530	20.5	8
360	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2086-2096	8.8	4
359	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2070-2085	8.8	10
358	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2183-2199	8.8	3
357	Astroglial tracer BU99008 detects multiple binding sites in Alzheimer's disease brain. <i>Molecular Psychiatry</i> , 2021 ,	15.1	12
356	In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue. <i>Journal of Alzheimer's Disease</i> , 2021 , 80, 1723-1737	4.3	10
355	Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis. <i>Neurology</i> , 2021 ,	6.5	23
354	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , 2021 , 20, 484-496	24.1	86
353	Subcortical and Cortical Regions of Amyloid-Pathology Measured by ¹¹ C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 1613-1624	4.3	0
352	Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy. <i>ACS Chemical Neuroscience</i> , 2021 , 12, 2437-2447	5.7	7
351	Clinical impact of F-FDG-PET among memory clinic patients with uncertain diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 612-622	8.8	5
350	In silico studies of ASEM analogues targeting α -nAChR and experimental verification. <i>RSC Advances</i> , 2021 , 11, 3942-3951	3.7	0
349	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2110-2120	8.8	9

348	Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils. <i>ACS Chemical Neuroscience</i> , 2021 , 12, 3487-3496	5.7	3
347	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021 , 84, 103-117	4.3	0
346	Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. <i>Molecular Psychiatry</i> , 2021 ,	15.1	7
345	Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis. <i>Neurology</i> , 2021 , 96, 238	6.5	1
344	Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. <i>Brain Communications</i> , 2020 , 2, fcaa192	4.5	5
343	Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid- β positivity. <i>Molecular Psychiatry</i> , 2020 ,	15.1	7
342	Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1031-1042	1.2	16
341	[F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2020 ,	15.1	8
340	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer's disease variants: A β Parc and PSEN1DE9. <i>Molecular Psychiatry</i> , 2020 ,	15.1	5
339	Computational Insight into the Binding Profile of the Second-Generation PET Tracer PI2620 with Tau Fibrils. <i>ACS Chemical Neuroscience</i> , 2020 , 11, 900-908	5.7	16
338	Biological subtypes of Alzheimer disease: A systematic review and meta-analysis. <i>Neurology</i> , 2020 , 94, 436-448	6.5	77
337	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , 2020 , 19, 951-962	24.1	95
336	Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. <i>Brain Connectivity</i> , 2020 , 10, 555-565	2.7	6
335	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1457-1468	1.2	16
334	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020 , 94, e2026-e2036	6.5	17
333	Homomeric and Heteromeric A β Species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype. <i>Frontiers in Molecular Neuroscience</i> , 2019 , 12, 176	6.1	4
332	Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [F]THK5317 PET. <i>NeuroImage: Clinical</i> , 2019 , 22, 101681	5.3	2
331	Free Energy Profile for Penetration of Pittsburgh Compound-B into the Amyloid β Fibril. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 1783-1790	5.7	7

330	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1081-1103	1.2	10
329	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 327-332	5.2	6
328	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1369-1382	8.8	45
327	Clinical impact of [F]flutemetamol PET among memory clinic patients with an unclear diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1276-1286	8.8	26
326	Spatial Normalization of F-Flutemetamol PET Images Using an Adaptive Principal-Component Template. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 285-291	8.9	23
325	Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes. <i>Neurobiology of Aging</i> , 2019 , 82, 40-47	5.6	1
324	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019 , 266, 2535-2545	5.5	6
323	CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019 , 12, 239	6.1	10
322	Astrocyte Biomarkers in Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , 2019 , 25, 77-95	11.5	108
321	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1152-1163	8.8	23
320	Tau PET imaging in neurodegenerative tauopathies-still a challenge. <i>Molecular Psychiatry</i> , 2019 , 24, 1112-1134	11.34	251
319	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019 , 15, 388-399	1.2	19
318	Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 348-356	8.8	23
317	Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 232-236	5.2	60
316	Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling. <i>ACS Chemical Neuroscience</i> , 2018 , 9, 1757-1767	5.7	43
315	Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 960-966	8.9	47
314	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 652-663	1.2	11
313	Prevalence of the apolipoprotein E $\epsilon 4$ allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924	1.2	36

312	Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. <i>Molecular Psychiatry</i> , 2018 , 23, 1666-1673	15.1	69
311	The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkers. <i>Neurobiology of Aging</i> , 2018 , 70, 18-29	5.6	31
310	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 45	9	5
309	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. <i>Methods in Molecular Biology</i> , 2018 , 1750, 231-251	1.4	14
308	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
307	The relevance of cerebrospinal fluid β -synuclein levels to sporadic and familial Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 130	7.3	24
306	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A β species. <i>NeuroImage: Clinical</i> , 2018 , 20, 603-610	5.3	7
305	Dual tracer tau PET imaging reveals different molecular targets for C-THK5351 and C-PBB3 in the Alzheimer brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 1605-1617	8.8	27
304	Comparability of [F]THK5317 and [C]PIB blood flow proxy images with [F]FDG positron emission tomography in Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017 , 37, 740-749	7.3	35
303	Tau PET imaging: present and future directions. <i>Molecular Neurodegeneration</i> , 2017 , 12, 19	19	172
302	Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by H-THK5117 and H-deprenyl autoradiography. <i>Scientific Reports</i> , 2017 , 7, 45496	4.9	29
301	Characterization of the binding mode of the PET tracer [18F]ASEM to a chimera structure of the α 7 nicotinic acetylcholine receptor. <i>RSC Advances</i> , 2017 , 7, 19787-19793	3.7	3
300	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017 , 52, 183-195	5.6	67
299	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017 , 52, 214-227	5.6	52
298	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017 , 13, 274-284	1.2	91
297	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017 , 13, 285-295	1.2	88
296	Development of [C]/[H]THK-5351 - A potential novel carbon-11 tau imaging PET radioligand. <i>Nuclear Medicine and Biology</i> , 2017 , 46, 50-53	2.1	12
295	A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 603-614	4.3	35

294	Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 96	9	65
293	Effect of Alzheimer Familial Chromosomal Mutations on the Amyloid Fibril Interaction with Different PET Tracers: Insight from Molecular Modeling Studies. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 2655-2666	5.7	6
292	Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. <i>Brain</i> , 2017 , 140, 764-780	11.2	125
291	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , 2017 , 16, 661-676	24.1	308
290	Quantitative positron emission tomography in brain research. <i>Brain Research</i> , 2017 , 1670, 220-234	3.7	27
289	Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 419-430	1.2	21
288	[P2866]: HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER'S DISEASE: [11C]THK5351 VERSUS [11C]PBB3 PET IMAGING 2017 , 13, P765-P765		1
287	[P4074]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES 2017 , 13, P1390-P1390		
286	[IC-P-016]: INVESTIGATING THE CLINICAL IMPACT OF [18F]FLUTEMETAMOL PET IN A TERTIARY MEMORY CLINIC SETTING IN PATIENTS WITH UNCERTAIN DIAGNOSIS 2017 , 13, P19-P20		
285	[IC-P-178]: HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER'S DISEASE: [11C]THK5351 VERSUS [11C]PBB3 PET IMAGING 2017 , 13, P133-P133		2
284	[IC-P-189]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES 2017 , 13, P139-P140		
283	[P1857]: INVESTIGATING THE CLINICAL IMPACT OF [18F]FLUTEMETAMOL PET IN A TERTIARY MEMORY CLINIC SETTING IN PATIENTS WITH UNCERTAIN DIAGNOSIS 2017 , 13, P394-P395		
282	Imaging of amyloid using [(18F)flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 362-373	8.8	28
281	Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. <i>Neurology</i> , 2016 , 86, 50-8	6.5	48
280	Theoretical study of the binding profile of an allosteric modulator NS-1738 with a chimera structure of the $\alpha 7$ nicotinic acetylcholine receptor. <i>Physical Chemistry Chemical Physics</i> , 2016 , 18, 28003-28009	3.6	6
279	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1316-22	8.9	94
278	Tracer Kinetic Analysis of (S)-[11C]-THK5117 as a PET Tracer for Assessing Tau Pathology. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 574-81	8.9	41
277	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016 , 139, 922-36	11.2	177

276	Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1686-99	8.8	98
275	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , 2016 , 15, 455-532	24.1	921
274	Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1071-7	8.9	47
273	Amyloid- β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BA β CS. <i>Brain</i> , 2016 , 139, 174-92	11.2	24
272	Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 30	9	82
271	P3-262: TAU PET Imaging in Non-Alzheimer's Disease Dementia: a Multimodal Paradigm 2016 , 12, P932-P933		
270	P1-306: Association Between in Vivo TAU Deposition Measured Using [18F]THK5317 Pet and Cognitive Functions in Alzheimer's Disease 2016 , 12, P539-P540		
269	IC-P-170: In Vitro Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic AD Brain in Comparison With Sporadic AD Brain Using 3H-PIB, 3H-THK5117 and 3H-Deprenyl 2016 , 12, P124-P124		
268	IC-P-189: TAU PET Imaging in Non-Alzheimer's Disease Dementia: A Multimodal Paradigm 2016 , 12, P137-P137		
267	O4-07-03: Longitudinal Changes in Regional Tau Deposition in Alzheimer's Disease and other Tauopathies Measured by [18F]-TKH5317 Pet in a Multi-Tracer Design 2016 , 12, P348-P349		
266	P1-105: In vitro Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic Alzheimer's Disease Brain in Comparison With Sporadic Alzheimer's Disease Brain Using 3H-PIB, 3H-THK5117 and 3H-DEPRENYL 2016 , 12, P442-P442		
265	P4-349: EARLY-PHASE [11C]PIB PET is Comparable to [18F]FDG PET as a Marker of Disease Progression in Alzheimer's Disease 2016 , 12, P1171-P1171		
264	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. <i>Brain</i> , 2016 , 139, 2540-53	11.2	93
263	Regional tau deposition measured by [F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 38	9	35
262	The Culprit Is in the Cave: The Core Sites Explain the Binding Profiles of Amyloid-Specific Tracers. <i>Journal of Physical Chemistry Letters</i> , 2016 , 7, 3313-21	6.4	29
261	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1316-28	1.2	41
260	Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1492-506	8.8	9
259	Astrocytosis precedes amyloid plaque deposition in Alzheimer APP ^{swE} transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1119-32	8.8	81

258	The use of amyloid imaging in clinical praxis: a critical review. <i>Clinical and Translational Imaging</i> , 2015 , 3, 7-11	2	4
257	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
256	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1939-49	27.4	379
255	Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. <i>Acta Neuropathologica Communications</i> , 2015 , 3, 40	7.3	50
254	Investigation of the Binding Profiles of AZD2184 and Thioflavin T with Amyloid- β (1-42) Fibril by Molecular Docking and Molecular Dynamics Methods. <i>Journal of Physical Chemistry B</i> , 2015 , 119, 11560-74	7.4	40
253	Molecular imaging of neuroinflammation in Alzheimer's disease. <i>Clinical and Translational Imaging</i> , 2015 , 3, 437-447	2	11
252	Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 438-46	8.8	54
251	Glial Asthenia and Functional Paralysis: A New Perspective on Neurodegeneration and Alzheimer's Disease. <i>Neuroscientist</i> , 2015 , 21, 552-568	7.6	64
250	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. <i>Alzheimer's and Dementia</i> , 2015 , 11, 195-206.e1	1.2	45
249	IC-P-126: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease 2015 , 11, P86-P86		
248	P4-254: Characterization of regional binding of clinical amyloid tracers in autosomal dominant and sporadic Alzheimer's disease brains and their interactions with resveratrol 2015 , 11, P878-P878		
247	O4-07-05: 18F-(S).THK5117 as a PET tracer for tau pathology in Alzheimer's disease and non-alzheimer's disease dementia 2015 , 11, P285-P285		
246	O1-02-03: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease 2015 , 11, P127-P127		
245	Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. <i>Scientific Reports</i> , 2015 , 5, 16404	4.9	79
244	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 661-7	4.3	10
243	Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic or Nicotinic Receptor Drugs. <i>Neural Plasticity</i> , 2015 , 2015, 370432	3.3	38
242	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1191-201	1.2	59
241	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset 2015 , 11, P140-P142		

240	Dementia in 2014. Towards early diagnosis in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2015 , 11, 69-70	15	41
239	Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer's disease case. <i>Neurocase</i> , 2015 , 21, 738-47	0.8	
238	Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 45, 1077-88	4.3	32
237	Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 691-704	4.3	7
236	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , 2014 , 13, 614-29	24.1	1985
235	Promising two-photon probes for in vivo detection of β amyloid deposits. <i>Chemical Communications</i> , 2014 , 50, 11694-7	5.8	21
234	Molecular imaging in sporadic Alzheimer's disease populations and those genetically at risk. <i>Neurodegenerative Diseases</i> , 2014 , 13, 160-2	2.3	5
233	Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors. <i>Journal of Alzheimer's Disease</i> , 2014 , 39, 423-40	4.3	17
232	O4-02-05: DIFFERENT TIME COURSE OF ASTROCYTOSIS AND AMYLOID DEPOSITION IN ALZHEIMER'S APPSWE TRANSGENIC MICE: A MULTI-TRACER MICROPET STUDY 2014 , 10, P253-P253		1
231	Astrocytosis measured by ^{11}C -deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 2120-6	8.8	46
230	PET Tracers for Beta-Amyloid and Other Proteinopathies 2014 , 199-212		2
229	^{11}C -deprenyl and ^{11}C -PIB autoradiography show different laminar distributions of astroglia and fibrillar β amyloid in Alzheimer brain. <i>Journal of Neuroinflammation</i> , 2013 , 10, 90	10.1	38
228	Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013 , 34, 2465-81	5.6	38
227	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 104-14	8.8	148
226	Imaging markers for Alzheimer disease: which vs how. <i>Neurology</i> , 2013 , 81, 487-500	6.5	173
225	Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. <i>Brain</i> , 2013 , 136, 2217-27	7.2	94
224	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , 2013 , 80, 1048-56	6.5	131
223	Combination of ^{18}F -FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 929-39	4.3	44

222	Modulation of $\alpha 7$ nicotinic acetylcholine receptor and fibrillar amyloid- β interactions in Alzheimer's disease brain. <i>Journal of Alzheimer's Disease</i> , 2013 , 33, 841-51	4.3	56
221	Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e54887	3.7	46
220	Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid- β levels. <i>PLoS ONE</i> , 2013 , 8, e58752	3.7	30
219	A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. <i>primary care companion for CNS disorders, The</i> , 2013 , 15,	1.2	174
218	Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012 , 33, 198.e1-14	5.6	103
217	Different β amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. <i>Neurobiology of Aging</i> , 2012 , 33, 825.e1-13	5.6	76
216	The use of PIB-PET as a dual pathological and functional biomarker in AD. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012 , 1822, 380-5	6.9	41
215	Apolipoprotein $\epsilon 4$ modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 443-58	4.3	27
214	Evidence for astrocytosis in prodromal Alzheimer disease provided by ^{11}C -deuterium-L-deprenyl: a multitracer PET paradigm combining ^{11}C -Pittsburgh compound B and ^{18}F -FDG. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 37-46	8.9	287
213	Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012 , 33, 18-28	2.6	93
212	Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. <i>Neurology</i> , 2012 , 79, 229-36	6.5	112
211	Characterization of the brain β amyloid isoform pattern at different ages of Tg2576 mice. <i>Neurodegenerative Diseases</i> , 2011 , 8, 352-63	2.3	16
210	Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , 2011 , 95, 579-93	10.9	100
209	The apolipoprotein E $\epsilon 4$ allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. <i>Neurobiology of Aging</i> , 2011 , 32, 1236-48	5.6	42
208	Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. <i>Neurobiology of Aging</i> , 2011 , 32, 1388-99	5.6	40
207	Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. <i>Neurobiology of Aging</i> , 2011 , 32, 2320.e15-32 ^{5,6}	5.6	41
206	Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. <i>Journal of Alzheimer's Disease</i> , 2011 , 24, 109-23	4.3	38
205	Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers. <i>Journal of Alzheimer's Disease</i> , 2011 , 24, 495-506 ^{4,3}	4.3	24

204	Interview: Imaging in Alzheimer's Disease. <i>Imaging in Medicine</i> , 2011 , 3, 389-392	1	
203	Functional interactions of fibrillar and oligomeric amyloid- β with $\alpha 7$ nicotinic receptors in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 23, 335-47	4.3	39
202	Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. <i>Alzheimer's Research and Therapy</i> , 2011 , 3, 34	9	36
201	Transgenic mice as a model for Alzheimer's disease. <i>Current Alzheimer Research</i> , 2011 , 8, 818-31	3	25
200	Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. <i>Journal of Lipid Research</i> , 2011 , 52, 1004-10	6.3	73
199	Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. <i>Brain</i> , 2011 , 134, 301-17	11.2	109
198	Amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons. <i>PLoS ONE</i> , 2010 , 5, e15600	3.7	35
197	Target-specific PET probes for neurodegenerative disorders related to dementia. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1418-30	8.9	47
196	Effect of huprine X on amyloid, synaptophysin and $\alpha 7$ neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice. <i>Neurodegenerative Diseases</i> , 2010 , 7, 379-88	2.3	28
195	Amyloid imaging in early detection of Alzheimer's disease. <i>Neurodegenerative Diseases</i> , 2010 , 7, 136-8	2.3	25
194	The use of PET in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010 , 6, 78-87	15	274
193	Neurotrophic factors promote cholinergic differentiation in human embryonic stem cell-derived neurons. <i>Journal of Cellular and Molecular Medicine</i> , 2010 , 14, 1476-84	5.6	40
192	The future: new methods of imaging exploration in Alzheimer's disease. <i>Frontiers of Neurology and Neuroscience</i> , 2009 , 24, 47-53	1.1	6
191	Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. <i>Current Alzheimer Research</i> , 2009 , 6, 4-14	3	57
190	A β (25-35) attenuated SREBP level in nuclear extracts of serum-deprived human neuroblastoma cells. <i>Neurochemical Research</i> , 2009 , 34, 845-50	4.6	1
189	[(11C)PIB-amyloid binding and levels of A β 40 and A β 42 in postmortem brain tissue from Alzheimer patients. <i>Neurochemistry International</i> , 2009 , 54, 347-57	4.4	72
188	Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 635-46	1.9	38
187	Amyloid imaging in Alzheimer's disease. <i>Neuropsychologia</i> , 2008 , 46, 1636-41	3.2	58

186	Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. <i>Neurobiology of Aging</i> , 2008 , 29, 168-84	5.6	54
185	PET imaging of amyloid deposition in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2008 , 29, 1456-65	5.6	533
184	Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 289-98	1.9	43
183	In vivo amyloid imaging with PET in frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 100-6	8.8	137
182	Amyloid plaque imaging in vivo: current achievement and future prospects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35 Suppl 1, S46-50	8.8	60
181	Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. <i>Annals of Neurology</i> , 2008 , 63, 621-31	9.4	111
180	Unidirectional Influx and Net Accumulation of PIB. <i>Open Neuroimaging Journal</i> , 2008 , 2, 114-25	0.1	44
179	Neurogenic neuroepithelial and radial glial cells generated from six human embryonic stem cell lines in serum-free suspension and adherent cultures. <i>Glia</i> , 2007 , 55, 385-99	9	122
178	Retinoic acid and nerve growth factor induce differential regulation of nicotinic acetylcholine receptor subunit expression in SN56 cells. <i>Journal of Neuroscience Research</i> , 2007 , 85, 504-14	4.4	9
177	Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. <i>Psychopharmacology</i> , 2007 , 191, 1005-14	4.7	47
176	Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 12506-11	11.5	72
175	Amyloid imaging in Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2007 , 20, 398-402	7.1	69
174	Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. <i>Neurochemistry International</i> , 2007 , 50, 800-6	4.4	21
173	The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. <i>Neurochemistry International</i> , 2007 , 51, 877-83	4.4	42
172	PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. <i>Psychopharmacology</i> , 2006 , 188, 509-20	4.7	109
171	Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. <i>Neurobiology of Disease</i> , 2006 , 24, 326-33	7.5	44
170	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. <i>Brain</i> , 2006 , 129, 2856-66	11.2	513
169	Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APP ^{swe}) transgenic mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 317, 30-6	4.7	51

168	Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. <i>Neurochemistry International</i> , 2006 , 49, 459-65	4.4	25
167	Expression of the alpha7, alpha4 and alpha3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice carrying genes coding for human AChE and beta-amyloid. <i>International Journal of Developmental Neuroscience</i> , 2006 , 24, 269-73	2.7	7
166	Emerging biology of the cholinergic system across the spectrum of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2006 , 18, S3-S16	3.4	8
165	Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006 , 20, S12-8	2.5	92
164	Feedback regulation of SREBP and aromatase in A beta(25-35)-supplemented human neuroblastoma cells. <i>Cellular and Molecular Neurobiology</i> , 2006 , 26, 225-35	4.6	6
163	Visualization of nicotinic and muscarinic receptors in brain by positron emission tomography 2006 , 181-190		1
162	Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the alpha7, alpha4 and beta2 subunits in response to nanomolar concentrations of the beta-amyloid peptide(1-42). <i>Neurochemistry International</i> , 2005 , 47, 281-90	4.4	60
161	Early changes in A beta levels in the brain of APPsw transgenic mice—implication on synaptic density, alpha7 neuronal nicotinic acetylcholine- and N-methyl-D-aspartate receptor levels. <i>Molecular and Cellular Neurosciences</i> , 2005 , 30, 218-27	4.8	13
160	High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. <i>Experimental Neurology</i> , 2005 , 192, 215-25	5.7	105
159	A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. <i>Trends in Pharmacological Sciences</i> , 2005 , 26, 104-11	13.2	114
158	Lovastatin stimulates up-regulation of alpha7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the alpha-form of secreted amyloid precursor protein. <i>Journal of Neuroscience Research</i> , 2005 , 82, 531-41	4.4	20
157	Follow-up study of amyloid deposition and glucose metabolism in patients with Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005 , 25, S415-S415	7.3	
156	Different patterns of PIB uptake in AD patients. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005 , 25, S666-S666	7.3	1
155	Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique. <i>Progress in Brain Research</i> , 2004 , 145, 301-10	2.9	12
154	Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. <i>European Journal of Neuroscience</i> , 2004 , 19, 2703-10	3.5	110
153	PET imaging of amyloid in Alzheimer's disease. <i>Lancet Neurology</i> , 2004 , 3, 519-27	24.1	358
152	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004 , 31, 1540-3	8.8	4
151	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. <i>Annals of Neurology</i> , 2004 , 55, 306-19	9.4	3088

150	Decreased nicotinic receptors in PC12 cells and rat brains influenced by fluoride toxicity--a mechanism relating to a damage at the level in post-transcription of the receptor genes. <i>Toxicology</i> , 2004 , 200, 169-77	4.4	45
149	Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase. <i>Neuropharmacology</i> , 2004 , 47, 558-71	5.5	12
148	Modulation of dopamine release by the nicotinic agonist epibatidine in the frontal cortex and the nucleus accumbens of naive and chronic nicotine treated rats. <i>Neurochemistry International</i> , 2004 , 45, 1049-55	4.4	12
147	Selective changes in expression of different nicotinic receptor subtypes in brain and adrenal glands of mice carrying human mutated gene for APP or over-expressing human acetylcholinesterase. <i>International Journal of Developmental Neuroscience</i> , 2004 , 22, 545-9	2.7	8
146	Toward an early diagnosis and treatment of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2003 , 15, 223-37	3.4	20
145	Higher expression of alpha7 nicotinic acetylcholine receptors in human fetal compared to adult brain. <i>Developmental Brain Research</i> , 2003 , 142, 151-60		31
144	Loss of nicotinic receptors induced by beta-amyloid peptides in PC12 cells: possible mechanism involving lipid peroxidation. <i>Journal of Neuroscience Research</i> , 2003 , 71, 397-406	4.4	21
143	Selective decreases of nicotinic acetylcholine receptors in PC12 cells exposed to fluoride. <i>Toxicology</i> , 2003 , 183, 235-42	4.4	21
142	A critical discussion of the role of neuroimaging in mild cognitive impairment. <i>Acta Neurologica Scandinavica</i> , 2003 , 179, 52-76	3.8	153
141	Correlation of oxidative stress and the loss of the nicotinic receptor alpha 4 subunit in the temporal cortex of patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 2003 , 338, 13-6	3.3	15
140	Neuronal nicotinic and muscarinic receptor subtypes at different ages of transgenic mice overexpressing human acetylcholinesterase. <i>Neuroscience Letters</i> , 2003 , 340, 148-52	3.3	14
139	Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. <i>Neurochemistry International</i> , 2003 , 43, 243-9	4.4	123
138	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. <i>Neuroimaging Clinics of North America</i> , 2003 , 13, 781-9, ix	3	60
137	Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002 , 13, 199-204	2.6	3
136	Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. <i>Journal of Neuroimmunology</i> , 2002 , 126, 50-7	3.5	136
135	Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. <i>Brain Research</i> , 2002 , 956, 358-66	3.7	50
134	Chronic fluoride toxicity decreases the number of nicotinic acetylcholine receptors in rat brain. <i>Neurotoxicology and Teratology</i> , 2002 , 24, 751-7	3.9	48
133	The alpha7 nicotinic receptors in human fetal brain and spinal cord. <i>Journal of Neurochemistry</i> , 2002 , 80, 457-65	6	40

132	Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). <i>Journal of Neurochemistry</i> , 2002 , 81, 655-8	6	142
131	Upregulation of neuronal nicotinic receptor subunits alpha4, beta2, and alpha7 in transgenic mice overexpressing human acetylcholinesterase. <i>Journal of Molecular Neuroscience</i> , 2002 , 18, 211-22	3.3	25
130	Smoking during pregnancy: a way to transfer the addiction to the next generation?. <i>Respiration</i> , 2002 , 69, 289-93	3.7	83
129	Selective nicotinic receptor consequences in APP(SWE) transgenic mice. <i>Molecular and Cellular Neurosciences</i> , 2002 , 20, 354-65	4.8	58
128	Elevated levels of Abeta1-40 and Abeta1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice. <i>Neuroscience Letters</i> , 2002 , 328, 269-72	3.3	19
127	Functional Activation Studies in Alzheimer Patients and Strategies in Drug Evaluation. <i>Advances in Behavioral Biology</i> , 2002 , 183-186		
126	Reduced expression of neuronal nicotinic acetylcholine receptors during the early stages of damage by oxidative stress in PC12 cells. <i>Journal of Neuroscience Research</i> , 2001 , 66, 551-8	4.4	30
125	Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. <i>Biological Psychiatry</i> , 2001 , 49, 200-10	7.9	273
124	Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. <i>Journal of Chemical Neuroanatomy</i> , 2001 , 22, 115-26	3.2	153
123	Expression of nicotinic acetylcholine receptors in human and rat adrenal medulla. <i>Life Sciences</i> , 2001 , 70, 577-90	6.8	30
122	Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. <i>Journal of Neurochemistry</i> , 2000 , 74, 777-84	6	59
121	Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2000 , 74, 237-43	6	214
120	Early diagnosis of Alzheimer disease with positron emission tomography. <i>Alzheimer Disease and Associated Disorders</i> , 2000 , 14 Suppl 1, S109-13	2.5	25
119	Apolipoprotein E varepsilon4 allele has an impact on vascular reactivity in Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> , 2000 , 31, 221-231	4	5
118	Neuroprotection in Alzheimer's disease - new strategies for treatment. <i>Neurotoxicity Research</i> , 2000 , 2, 157-65	4.3	15
117	Preface. <i>Behavioural Brain Research</i> , 2000 , 113, 1	3.4	
116	Rats exhibiting acute behavioural tolerance to nicotine have more [125I]alpha-bungarotoxin binding sites in brain than rats not exhibiting tolerance. <i>Behavioural Brain Research</i> , 2000 , 113, 105-15	3.4	9
115	Development of ligands for in vivo imaging of cerebral nicotinic receptors. <i>Behavioural Brain Research</i> , 2000 , 113, 143-57	3.4	79

114	Neuronal nicotinic receptors in the human brain. <i>Progress in Neurobiology</i> , 2000 , 61, 75-111	10.9	641
113	Influence of lipid peroxidation on the nicotinic acetylcholine receptors in PC12 cells. <i>Neuroscience Letters</i> , 2000 , 286, 163-6	3.3	11
112	Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2000 , 111, 1817-24	4.3	241
111	Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. <i>Journal of Neurochemistry</i> , 1999 , 72, 1161-9	6	51
110	Synthesis and characterization of binding of 5-[76Br]bromo-3-[[2(S)-azetidiny]methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. <i>Journal of Neurochemistry</i> , 1999 , 73, 1264-72	6	20
109	In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C]MPA compared with [11C]ABT-418 and (S)(-)[11C]nicotine in rhesus monkeys. <i>Nuclear Medicine and Biology</i> , 1999 , 26, 633-40	2.1	28
108	Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. <i>Molecular Brain Research</i> , 1999 , 66, 94-103		167
107	A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999 , 10, 526-33	2.6	27
106	Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. <i>NeuroReport</i> , 1999 , 10, 1779-82	1.7	252
105	Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (+/-)-[3H]epibatidine. <i>Brain Research</i> , 1998 , 801, 143-9	3.7	85
104	Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. <i>Developmental Brain Research</i> , 1998 , 108, 147-60		133
103	Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1998 , 357, 176-82	3.4	52
102	Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidone (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex. <i>Neurochemistry International</i> , 1998 , 32, 435-41	4.4	14
101	Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 1998 , 254, 85-8	3.3	44
100	Postnatal changes of nicotinic acetylcholine receptor alpha 2, alpha 3, alpha 4, alpha 7 and beta 2 subunits genes expression in rat brain. <i>International Journal of Developmental Neuroscience</i> , 1998 , 16, 507-18	2.7	107
99	Differential changes of nicotinic receptors in the rat brain following ibotenic acid and 192-IgG saporin lesions of the nucleus basalis magnocellularis. <i>International Journal of Developmental Neuroscience</i> , 1998 , 16, 661-8	2.7	13
98	Chronic ethanol treatment decreases [3H]epibatidine and [3H]nicotine binding and differentially regulates mRNA levels of nicotinic acetylcholine receptor subunits expressed in M10 and SH-SY5Y neuroblastoma cells. <i>Journal of Neurochemistry</i> , 1998 , 70, 1134-42	6	27
97	Regulation of nicotinic receptor subtypes following chronic nicotinic agonist exposure in M10 and SH-SY5Y neuroblastoma cells. <i>Journal of Neurochemistry</i> , 1998 , 70, 2028-37	6	42

96	In vitro evaluation of ¹¹ C-labeled (S)-nicotine, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (R,S)-1-methyl-2-(3-pyridyl)azetidone as nicotinic receptor ligands for positron emission tomography studies. <i>Journal of Neurochemistry</i> , 1998 , 71, 1750-60	6	16
95	Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. <i>Drug Safety</i> , 1998 , 19, 465-80	5.1	250
94	Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998 , 9, 246-57	2.6	363
93	Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. <i>Alzheimer Disease and Associated Disorders</i> , 1998 , 12, 228-37	2.5	58
92	(S)-(-)-[¹¹ C]nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain. <i>Alzheimer Disease and Associated Disorders</i> , 1998 , 12, 238-46	2.5	23
91	Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. <i>NeuroReport</i> , 1998 , 9, 1519-22	1.7	80
90	Nicotinic Receptors as a new Target for Treatment of Alzheimer's Disease. <i>Advances in Behavioral Biology</i> , 1998 , 463-468		
89	Regional brain distribution and binding of the muscarinic receptor agonist CI-979 studied by positron emission tomography in the monkey. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997 , 8, 259-66 ^{2.6}		5
88	Brain activation in young and older adults during implicit and explicit retrieval. <i>Journal of Cognitive Neuroscience</i> , 1997 , 9, 378-91	3.1	186
87	Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997 , 8, 78-84	2.6	83
86	Use of carbon-11 nicotine in PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997 , 24, 825-6		6
85	Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. <i>Neuroscience Letters</i> , 1997 , 232, 37-40	3.3	36
84	Muscarinic receptor subtypes in subpopulations of human blood mononuclear cells as analyzed by RT-PCR technique. <i>Journal of Neuroimmunology</i> , 1996 , 68, 139-44	3.5	41
83	Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996 , 7, 111-7	2.6	10
82	Differential co-expression of nicotinic acetylcholine receptor alpha 4 and beta 2 subunit genes in various regions of rat brain. <i>NeuroReport</i> , 1996 , 7, 1645-9	1.7	12
81	Tacrine interacts with an allosteric activator site on alpha 4 beta 2 nAChRs in M10 cells. <i>NeuroReport</i> , 1996 , 7, 2201-5	1.7	34
80	Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors. <i>Brain Research</i> , 1996 , 726, 207-212	3.7	25
79	Apolipoprotein E epsilon4 allele, skin vessel reactivity and vascular risk factors in Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> , 1996 , 22, 223-32	4	1

78	Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 593-4	6.1	49
77	Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. <i>NeuroReport</i> , 1995 , 6, 2419-23	1.7	135
76	Kinetic analysis of regional (S)(-)-11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography. <i>Alzheimer Disease and Associated Disorders</i> , 1995 , 9, 21-7	2.5	177
75	Regulation of alpha 4 beta 2 nicotinic acetylcholine receptors in M10 cells following treatment with nicotinic agents. <i>NeuroReport</i> , 1995 , 6, 313-7	1.7	32
74	Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 57, 309-17	6.1	82
73	Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. <i>Behavior Genetics</i> , 1995 , 25, 149-59	3.2	76
72	Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. <i>Journal of Neurology</i> , 1994 , 242, S12-5	5.5	40
71	Effects of chronic treatment with (+)- and (-)-nicotine on nicotinic acetylcholine receptors and N-methyl-D-aspartate receptors in rat brain. <i>Brain Research</i> , 1994 , 644, 32-9	3.7	41
70	Human nicotinic receptors--their role in aging and dementia. <i>Neurochemistry International</i> , 1994 , 25, 93-7	4.4	102
69	Clinical studies in Alzheimer patients with positron emission tomography. <i>Behavioural Brain Research</i> , 1993 , 57, 215-24	3.4	59
68	Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. <i>Behavioural Brain Research</i> , 1993 , 57, 255-61	3.4	130
67	Coupling of muscarinic receptors to GTP proteins in postmortem human brain--alterations in Alzheimer's disease. <i>Neuroscience Letters</i> , 1993 , 150, 39-43	3.3	64
66	In vivo detection of neurotransmitter changes in Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 1993 , 695, 27-33	6.5	25
65	The competition of (-)-[3H]nicotine binding by the enantiomers of nicotine, nornicotine and anatoxin-a in membranes and solubilized preparations of different brain regions of rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1993 , 348, 28-34	3.4	38
64	Muscarinic and nicotinic receptor changes in the cortex and thalamus of brains of chronic alcoholics. <i>Brain Research</i> , 1993 , 620, 42-8	3.7	24
63	Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. <i>Neurobiology of Aging</i> , 1992 , 13, 747-58	5.6	135
62	Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. <i>Brain Research</i> , 1992 , 596, 142-8	3.7	64
61	Biological markers and the cholinergic hypothesis in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 1992 , 139, 54-8	3.8	45

60	Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs. <i>British Journal of Pharmacology</i> , 1991 , 104, 15-20	8.6	7
59	Temporal studies of the inhibition of voluntary ethanol intake in the rat induced by intermittent ethanol treatment and some long term neurochemical consequences. <i>Drug and Alcohol Dependence</i> , 1991 , 28, 129-44	4.9	6
58	Neonatal nicotine exposure induces permanent changes in brain nicotinic receptors and behaviour in adult mice. <i>Developmental Brain Research</i> , 1991 , 63, 201-7		72
57	Pharmacological modulation of transmitter activity in Alzheimer brains--an experimental model. <i>Acta Neurologica Scandinavica</i> , 1990 , 129, 17-20	3.8	1
56	New approaches to clinical and postmortem investigations of cholinergic mechanisms. <i>Progress in Brain Research</i> , 1990 , 84, 313-20	2.9	1
55	Future prospects of research on central cholinergic mechanisms. <i>Progress in Brain Research</i> , 1990 , 84, 415-8	2.9	3
54	Effects of two pyrethroids, bioallethrin and deltamethrin, on subpopulations of muscarinic and nicotinic receptors in the neonatal mouse brain. <i>Toxicology and Applied Pharmacology</i> , 1990 , 102, 456-63 ^{4.6}		65
53	Influence of development and aging on nicotinic receptor subtypes in rodent brain. <i>International Journal of Developmental Neuroscience</i> , 1990 , 8, 715-21	2.7	36
52	Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain. <i>European Journal of Pharmacology</i> , 1990 , 186, 301-5	5.3	18
51	Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. <i>Brain Research</i> , 1990 , 521, 329-32	3.7	60
50	Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres. <i>Neuroscience Letters</i> , 1989 , 101, 247-52	3.3	49
49	Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. <i>Biochemical and Biophysical Research Communications</i> , 1989 , 165, 766-71	3.4	97
48	Effect of nicotine on the release of acetylcholine and amino acids in the brain. <i>Progress in Brain Research</i> , 1989 , 79, 149-55	2.9	22
47	Long-term effects on biotransformation of labelled choline in different parts of the rat brain induced by single choline injections. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1988 , 62, 69-73		3
46	Distribution of nicotinic receptors in human thalamus as visualized by 3H-nicotine and 3H-acetylcholine receptor autoradiography. <i>Journal of Neural Transmission</i> , 1988 , 73, 77-83	4.3	34
45	Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex. <i>Journal of Neural Transmission</i> , 1988 , 72, 11-8	4.3	6
44	Relation between voluntary ethanol intake in rats and changes in striatal muscarinic binding sites seen after induction of stable ethanol intake by an intermittent ethanol treatment. <i>Brain Research</i> , 1988 , 474, 189-91	3.7	6
43	Influence of age on effects induced by intermittent ethanol treatment on the ethanol drinking pattern and related neurochemical changes in the rat. <i>Drug and Alcohol Dependence</i> , 1988 , 22, 117-28	4.9	4

42	Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. <i>Neuroscience Letters</i> , 1988 , 86, 317-21	3-3	81
41	[3H]acetylcholine nicotinic recognition sites in human brain: characterization of agonist binding. <i>Neuroscience Letters</i> , 1987 , 83, 298-302	3-3	23
40	In vitro binding of 3H-acetylcholine to nicotinic receptors in rodent and human brain. <i>Journal of Neural Transmission</i> , 1987 , 69, 3-18	4-3	13
39	Cholinergic topography in Alzheimer brains: a comparison with changes in the monoaminergic profile. <i>Journal of Neural Transmission</i> , 1987 , 69, 19-32	4-3	19
38	[3H]muscimol and [3H]quinuclidinyl benzilate binding in rat cortex in the abstinence after long-term barbital treatment. <i>Acta Physiologica Scandinavica</i> , 1986 , 126, 153-6		8
37	Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level. <i>Journal of Neural Transmission</i> , 1986 , 67, 275-85	4-3	94
36	Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type. <i>Neuroscience Letters</i> , 1986 , 70, 160-4	3-3	29
35	Subchronic treatment of rats with nicotine: effects on tolerance and on [3H]acetylcholine and [3H]nicotine binding in the brain. <i>Drug and Alcohol Dependence</i> , 1986 , 17, 37-45	4-9	29
34	Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. <i>Neuroscience Letters</i> , 1986 , 72, 115-9	3-3	386
33	Modulation of choline transport and acetylcholine synthesis in synaptosomes from different brain regions. <i>Acta Pharmacologica Et Toxicologica</i> , 1985 , 56, 193-8		3
32	Effect of nicotine on passive avoidance behaviour and motoric activity in mice. <i>Acta Pharmacologica Et Toxicologica</i> , 1985 , 56, 337-41		34
31	Comparative analysis of nicotine-like receptor-ligand interactions in rodent brain homogenate. <i>Journal of Neurochemistry</i> , 1985 , 45, 24-31	6	67
30	The effect of nicotine and cytisine on 3H-acetylcholine release from cortical slices of guinea-pig brain. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1985 , 331, 293-6	3-4	57
29	Regional [(3)H]acetylcholine and [(3)H]nicotine binding in developing mouse brain. <i>International Journal of Developmental Neuroscience</i> , 1985 , 3, 667-71	2-7	35
28	Effect of long-term nicotine treatment on [3H]nicotine binding sites in the rats brain. <i>Drug and Alcohol Dependence</i> , 1985 , 16, 9-17	4-9	49
27	Different interactions of steric isomers of hexobarbital to muscarinic agonist and antagonist binding sites in brain. <i>Brain Research</i> , 1984 , 310, 189-92	3-7	10
26	Muscarinic binding sites in small homogenates and in autoradiographic sections from rat and human spinal cord. <i>Brain Research</i> , 1984 , 300, 327-33	3-7	28
25	Pharmacodynamic effects of nicotine and acetylcholine biosynthesis in mouse brain. <i>Acta Pharmacologica Et Toxicologica</i> , 1983 , 52, 341-7		12

24	Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). <i>Neurobiology of Aging</i> , 1983 , 4, 261-71	5.6	287
23	Muscarinic receptor compensation in hippocampus of Alzheimer patients. <i>Journal of Neural Transmission</i> , 1983 , 56, 13-9	4.3	80
22	The regulation in vitro of placental release of human chorionic gonadotropin, placental lactogen, and prolactin: effects of an adrenergic beta-receptor agonist and antagonist. <i>American Journal of Obstetrics and Gynecology</i> , 1982 , 143, 444-50	6.4	22
21	Changes in populations of cholinergic binding sites in brain after chronic exposure to barbital in rats. <i>Brain Research</i> , 1982 , 246, 105-12	3.7	24
20	Tolerance, physical dependence and changes in muscarinic receptor binding sites after chronic ethanol treatment in the rat. <i>Life Sciences</i> , 1982 , 31, 277-87	6.8	23
19	Cholinergic activity in hippocampus in chronic alcoholism. <i>Drug and Alcohol Dependence</i> , 1982 , 10, 333-44.	4.9	39
18	Effect of denervation on acetylcholine synthesizing activity and nicotine-like binding sites in rat hind limb muscles. <i>Acta Physiologica Scandinavica</i> , 1982 , 114, 345-50		8
17	Atropine modulates changes in striatal muscarinic receptor binding sites in barbital abstinence in the rat. <i>Acta Physiologica Scandinavica</i> , 1982 , 115, 369-71		2
16	Acetylcholine synthesizing activity and nicotinic binding sites in rat hind limb muscles during reinnervation. <i>Acta Physiologica Scandinavica</i> , 1982 , 116, 429-35		16
15	Cholinergic receptors in human hippocampus-- regional distribution and variance with age. <i>Life Sciences</i> , 1981 , 29, 1937-44	6.8	103
14	Chronic nicotine exposure in rat: a behavioural and biochemical study of tolerance. <i>Drug and Alcohol Dependence</i> , 1981 , 8, 51-60	4.9	40
13	Changes in cholinergic function in rat brain late in abstinence after chronic barbital treatment. <i>Drug and Alcohol Dependence</i> , 1981 , 7, 51-61	4.9	14
12	Diurnal fluctuation in striatal choline acetyltransferase activity and strain difference in brain protein content of the rat. <i>Acta Physiologica Scandinavica</i> , 1980 , 108, 385-8		8
11	Increased number of muscarinic binding sites in brain following chronic barbiturate treatment to rat. <i>Life Sciences</i> , 1980 , 26, 231-7	6.8	26
10	Regional biosynthesis of acetylcholine in brain following forced oral chronic barbitone treatment to rat. <i>Journal of Neurochemistry</i> , 1979 , 32, 371-8	6	19
9	Effect of oxotremorine on the apparent regional turnover of acetylcholine in mouse brain. <i>Journal of Neurochemistry</i> , 1978 , 30, 383-9	6	18
8	Regional high affinity synaptosomal transport of choline in mouse brain--influence of oxotremorine treatment. <i>Life Sciences</i> , 1978 , 23, 937-44	6.8	17
7	Decreased brain weights in rats after long-term barbital treatments. <i>Life Sciences</i> , 1978 , 23, 1583-90	6.8	14

6	Effect of oxotremorine and sodium pentobarbitone on the pharmacokinetics of intravenous tracer doses of radioactive choline. <i>Journal of Pharmacy and Pharmacology</i> , 1977 , 29, 96-8	4.8	5
5	Effect of sodium pentobarbital on the apparent turnover of acetylcholine in different brain regions. <i>Acta Physiologica Scandinavica</i> , 1977 , 99, 336-44		33
4	Effect of oxotremorine on endogenous acetylcholine and on uptake and biotransformation of radioactive choline in discrete regions of mouse brain in vivo. <i>Biochemical Pharmacology</i> , 1976 , 25, 135-40	6	17
3	Biosynthesis of acetylcholine in different brain regions in vivo following alternative methods of sacrifice by microwave irradiation. <i>Acta Physiologica Scandinavica</i> , 1976 , 98, 307-17		25
2	Imaging and behavior in Parkinson's disease: functional imaging	89-96	
1	Brain Functional Imaging in Early and Preclinical Alzheimer's Disease	153-164	4